Valneva is a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines for infectious diseases. 
We take a highly specialized and targeted approach to vaccine development by focusing on vaccine solutions addressing unmet medical needs to ensure we can make a difference to peoples’ lives. We apply our deep understanding of vaccine science, including our expertise across multiple vaccine modalities, and our established vaccine development capabilities, to develop vaccines against diseases which are not yet vaccine-preventable, or for which there are limited effective treatment options. 
Today, we are leveraging our expertise and capabilities to rapidly advance a broad range of vaccines into and through the clinic, including candidates against the chikungunya virus and Lyme disease.
Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the U.S. with ~700 employees.

Scottish Enterprise

Deerfield

OrbiMed

Pfizer

Bpifrance

Deep Track Capital

Valneva

At Valneva, we are active in the fight against neglected tropical diseases. Join us - #UniteActEliminate. 
#WorldNTDDay #BeatNTDs www.worldntdday.org

Thailand reports more than 300% increase in Zika infections in 2023
https://lnkd.in/euTyh3dw

📣 2024 Finalist Announcement📣

Scotland's Life Sciences Awards 2024 finalists have been carefully selected, each highlighting exceptional achievements within the life sciences industry. This year's competition has been fierce, showcasing the breadth and depth of talent and innovation present in Scotland. The esteemed panel of judges, comprised of industry experts and leaders, faced the challenging task of selecting our 2024 finalists listed below. 

📈 Business Leadership Award - sponsored by Valneva
Antibody Analytics
Gary Beale, Emblation 
Dr Stephen Myatt, Macomics 

💡Innovative Collaboration – sponsored by GenScript 
Medicines Manufacturing Innovation Centre – Digital Membership, CPI 
Penrhos Bio Ltd 

⭐️Rising Star: Extraordinary Talent – sponsored by Charles River Laboratories 
Dr Stuart Hannah, Microplate Dx Limited Dx 
Professor Craig Ritchie, Scottish Brain Sciences
Dr Helge Dorfmueller, University of Dundee and RHAPSEDA

🏅Outstanding Skills Development – sponsored by SRG 
Piramal Pharma Solutions
Terumo Aortic
Valneva Scotland Ltd

💊Innovation – Pharm Services and Drug Discovery – sponsored by PCI 
RoslinCT CT 
Tay Therapeutics Ltd  
Valneva Scotland Ltd

🔬Innovation – Health Technology – sponsored by Piramal Group 
Fitabeo Therapeutics
IBISVISION 
Dr Luigi Manfredi, Softech Robotics

🐟 Innovation – Animal Health, Agritech and Aquaculture – sponsored by Highlands and Islands Enterprise 
Aquanzo Limited
MI:RNA Diagnostics
Tritonia Scientific Ltd 

♻️Sustainability – sponsored by RoslinCT 
Booth Welsh 
carbogenics 
CMAC c/o University of Strathclyde

🏆The LifetimeAchievement Award, sponsored by AstraZeneca, will be announced at the awards 
 
The winners in each category will be announced at the Scotland's Life Sciences Awards on Thursday 14th March where leaders, innovators, and stakeholders from the life sciences community will come together in an evening of celebration.
 
For more information about the Scotland's Life Sciences Awards 2024 and to #purchase #tickets please visit https://lnkd.in/dPhZDF7

#congratulations #finalists #awards #lifesciences #scotland #booknow

Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine 
https://lnkd.in/ep2Cmrzj

Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum
https://lnkd.in/eabJXeK4

Vaccination reduces pressure on our healthcare systems by helping to prevent health complications from over 30 infectious diseases. This allows healthcare professionals to give patients the care they need, when they need it #WeWontRest #VaccinesForLife #TeamVaccines

Valneva Provides Updated 2023 Financial Guidance
https://lnkd.in/ePx2THBx

Si les taux de couverture vaccinale sont en général élevés chez les nourrissons, ils chutent drastiquement à partir de l’adolescence, et plus encore à l’âge adulte. 
Pourtant, la #vaccination pourrait sauver 50 millions de vies dans le monde au cours de cette dernière décennie.


➡️  Le #Leem propose :

▶️ De mettre à disposition des professionnels de santé les données de couverture vaccinale de leur patientèle
▶️ D'accompagner les recommandations vaccinales d’une communication transparente, claire et explicative 
aux professionnels de #santé et au grand public
▶️ De multiplier le nombre d'effecteurs

Faire de la politique vaccinale un des piliers du systeme de santé est l'un des 3 grands défis identifiés par le comité vaccin des entreprises du #médicament. 👉 https://lnkd.in/e887egky 

#VaccinesForLife IFPMA AstraZeneca GSK  Mylan MSD France Pfizer Sanofi Valneva Viatris

Today, we observe the United Nations International Day of Epidemic Preparedness.
Infectious diseases can have a truly devastating impact on individuals’ health and the well-being of society at large. We work to advance vaccines for better lives, knowing that immunization is one of the most important tools we have in the fight against current and future epidemics.
#InfectiousDisease #EpidemicPreparedness

🌟From all of us here at Valneva, we wish you a magical holiday season and a very happy 2024✨
https://lnkd.in/dxq5ae3b 
#SeasonsGreetings #BaanDekFoundation

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

COM:VALNEVA

Valneva SE

Last Close

2.05

25/11 09:24

Market Cap

468.39M

Beta: -

Volume Today

96.35K

Avg: -

Filings Not Available